Postmenopausal Women Clinical Trial
Official title:
Acute Blood Pressure-lowering Effects of Beetroot Juice in Postmenopausal Women With and Without Hypertension
Verified date | June 2022 |
Source | Penn State University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In this study the investigators will test the hypothesis that acute consumption of inorganic nitrate (supplied in concentrated beetroot juice) reduces artery stiffness and resting blood pressure, and lessens the rise in blood pressure during handgrip exercise in postmenopausal women. Understanding and improving artery function and blood pressure regulation in women is important because they undergo accelerated arterial stiffening after menopause and have much larger increases in blood pressure when they exercise compared with either premenopausal women or men of similar age.
Status | Completed |
Enrollment | 16 |
Est. completion date | January 2020 |
Est. primary completion date | September 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 55 Years to 80 Years |
Eligibility | Inclusion Criteria: - Resting systolic blood pressure less than or equal to 160 mmHg - Resting diastolic blood pressure less than or equal to 100 mmHg Exclusion Criteria: - Overt cardiovascular, metabolic, hematologic, pulmonary, renal, musculoskeletal, and/or neurological disease(s) - Users of any tobacco and/or nicotine products (smokers, chewing tobacco, nicotine-containing patches/gum, smokeless cigarettes) - Body mass index greater than 35 - Total cholesterol greater than 239 mg/dl - LDL cholesterol greater than 159 mg/dl - Fasting blood triglycerides greater than 199 mg/dl - Fasting blood glucose greater than 109 mg/dl and HbA1c greater than 6.0% - Individuals currently taking any of the following medications: 1. blood pressure lowering medication (e.g., beta blockers, ACE inhibitors, angiotensin antagonists, calcium channel blockers, diuretics) 2. lipid-lowering medication (e.g., statins) 3. nitrates (e.g. nitroglycerin) for angina 4. phosphodiesterase inhibitors (e.g., Viagra) 5. anti-inflammatory drugs - Individuals currently taking hormone replacement therapy |
Country | Name | City | State |
---|---|---|---|
United States | Penn State University | University Park | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Penn State University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Resting Aortic Blood Pressures | Aortic Blood pressures were measured in the arm (cuff) and estimated in the aorta (radial artery tonometry). | Resting systolic blood pressure at 90 minutes after beetroot juice ingestion | |
Secondary | Blood Measures of Nitrate Absorption and Conversion | Venous blood will be withdrawn (venipuncture) for determination of plasma nitrate and nitrite. | Change from baseline measures of plasma nitrate and nitrite at 90 minutes and at approximately 6 hours | |
Secondary | Resting Arterial Stiffness/Wave Properties | Carotid to femoral artery pulse wave velocity will be assessed using arterial tonometry. | Change from baseline resting pulse wave velocity at 90 minutes after beet root juice ingestion | |
Secondary | Handgrip Exercise Blood Pressure Responses (Relative Change From Baseline) | Beat-to-beat blood pressure (finger cuff) will be assessed at rest and during handgrip exercise to volitional fatigue. | Approximately 180 minutes after ingestion of beetroot juice | |
Secondary | Peak Rate of Perceived Exertion Scores During Handgrip Exercise | The Borg Rating of Perceived Exertion Scale (RPE) was used to assess exercise intensity during handgrip exercise. The RPE scale ranges from a minimum of 6 (no exertion at all) to a maximum of 20 (maximal exertion) units on a scale. | Approximately 90 minutes after ingestion of beetroot juice | |
Secondary | Handgrip Exercise Tolerance | Time to fatigue (seconds) was assessed during a progressive blood flow restricted handgrip exercise protocol. | Approximately 90 minutes after ingestion of beetroot juice |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00932152 -
Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT01740076 -
Soy Nuts and Cardiovascular Risk in Postmenopausal Women
|
N/A | |
Recruiting |
NCT01259661 -
Physical Activity and Metabolic Risk Factors in Postmenopausal Women
|
N/A | |
Completed |
NCT00763464 -
Coronary Artery Disease (CAD) in Postmenopausal Women
|
N/A | |
Completed |
NCT00745108 -
Tibolone Endometrium Study (Study 32972)(P06470)
|
Phase 3 | |
Completed |
NCT03644472 -
Postmenopausal Women and Their Endothelium
|
Phase 2 | |
Terminated |
NCT05627791 -
Effects of Vaginal Oxytocin Gel on Vaginal Cytologic Parameters in Postmenopausal Woman
|
Phase 2/Phase 3 | |
Recruiting |
NCT01472393 -
Creatine on Bone Mass in Postmenopausal Women
|
N/A | |
Recruiting |
NCT05964673 -
Effect of Bioptron Light Therapy on Dryness of Eyes in Postmenopausal Women
|
N/A | |
Completed |
NCT04762095 -
The Effect of Mindfulness Stress Reduction Program on Menopausal Complaints and Quality of Life
|
N/A | |
Recruiting |
NCT01376934 -
Clinical Trial of Hysteroscopy in Postmenopausal Women to Compare Techniques
|
N/A | |
Recruiting |
NCT03705845 -
Tocotrienols for Obesity of Postmenopausal Women
|
Phase 1/Phase 2 | |
Completed |
NCT03940924 -
HIIT + RT on Body Composition and Gut Microbiota in Postmenopausal Women (PACWOMan)
|
N/A | |
Completed |
NCT00065546 -
Human Requirements for the Nutrient Choline
|
N/A | |
Completed |
NCT03191513 -
The Acute Effects of Interesterification of Commercially Used Fats on Postprandial Fat Metabolism
|
N/A | |
Completed |
NCT03492983 -
Effect of High Cocoa Content Chocolate on Health in Postmenopausal Women.
|
N/A | |
Recruiting |
NCT06042673 -
Impact of Pomegranate Seed Oil on Postprandial Cardiovascular Disease Risk Markers
|
N/A | |
Completed |
NCT00577720 -
Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate
|
Phase 2 | |
Completed |
NCT02094144 -
Health Benefits of a 6-month Brisk Walking Program in Sedentary Postmenopausal Women
|
N/A | |
Recruiting |
NCT05727228 -
Screening Triage and Risk Stratification
|